Loading...
XSHG603079
Market cap345mUSD
Dec 25, Last price  
14.11CNY
1D
-1.00%
1Q
38.25%
IPO
22.11%
Name

Zhejiang Shengda Bio-pharm Co Ltd

Chart & Performance

D1W1MN
XSHG:603079 chart
P/E
—
P/S
3.28
EPS
—
Div Yield, %
0.43%
Shrs. gr., 5y
1.62%
Rev. gr., 5y
8.10%
Revenues
727m
-1.44%
449,254,400398,770,700380,897,097536,429,474482,147,681508,561,120492,709,861519,149,812867,314,752789,732,754738,019,050727,405,727
Net income
-54m
L
52,360,20054,591,70043,785,14686,702,93760,935,61572,610,20244,544,42547,030,263197,438,34075,756,47331,484,427-54,062,930
CFO
64m
+58.22%
110,080,900105,279,80034,401,628148,071,83973,001,50495,334,03188,685,91258,553,623333,201,87574,460,43940,717,54664,421,472
Dividend
Jun 12, 20240.06 CNY/sh
Earnings
May 09, 2025

Profile

Zhejiang Shengda Bio-Pharm Co., Ltd. engages in the research, development, production, and sale of food and feed additives worldwide. The company offers vitamins, such as biotin and folic acid, etc.; biological fresh-keeping agents, including nisin and natamycin; and intermediate APIs. It also produces natural food preservatives. The company is based in Tiantai, China.
URL
https://www.sd-pharm.com/
IPO date
Aug 23, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
727,406
-1.44%
738,019
-6.55%
789,733
-8.95%
Cost of revenue
717,185
671,873
648,282
Unusual Expense (Income)
NOPBT
10,220
66,146
141,451
NOPBT Margin
1.41%
8.96%
17.91%
Operating Taxes
8,894
6,084
8,219
Tax Rate
87.02%
9.20%
5.81%
NOPAT
1,326
60,062
133,231
Net income
(54,063)
-271.71%
31,484
-58.44%
75,756
-61.63%
Dividends
(10,271)
(23,966)
(59,916)
Dividend yield
0.42%
1.12%
2.02%
Proceeds from repurchase of equity
(10,576)
BB yield
0.43%
Debt
Debt current
94,298
33,231
156,303
Long-term debt
144,304
609
1,742
Deferred revenue
5,464
7,583
6,946
Other long-term liabilities
1
1
Net debt
(98,833)
(347,578)
(367,403)
Cash flow
Cash from operating activities
64,421
40,718
74,460
CAPEX
(245,927)
Cash from investing activities
(241,519)
2,546
Cash from financing activities
176,980
FCF
(92,474)
28,653
157,741
Balance
Cash
326,736
320,718
514,762
Long term investments
10,700
60,700
10,686
Excess cash
301,066
344,517
485,961
Stockholders' equity
609,762
674,251
667,777
Invested Capital
1,212,687
1,026,245
1,002,672
ROIC
0.12%
5.92%
13.41%
ROCE
0.67%
4.80%
9.45%
EV
Common stock shares outstanding
168,947
171,189
171,189
Price
14.57
16.10%
12.55
-27.46%
17.30
-19.91%
Market cap
2,461,553
14.57%
2,148,421
-27.46%
2,961,569
-18.75%
EV
2,378,029
1,816,292
2,610,660
EBITDA
82,833
134,393
212,769
EV/EBITDA
28.71
13.51
12.27
Interest
1,834
4,559
5,759
Interest/NOPBT
17.95%
6.89%
4.07%